Phase 2 Completed N=12 Randomized Triple-blind Treatment

Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers

Sports Concussion

Source: ClinicalTrials.gov NCT01321151 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Feb 2021

Primary outcomePrimary: Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events. — 1.57; 1.24 AST/ALT ratio

Summary

Sports-related concussions are a serious problem in football, boxing, and other full contact sports. After experiencing consecutive concussions, there is an increase in neurological deficits that can lead to long-term cognitive problems (Dementia pugilistica). To combat this increase in brain damage, novel strategies need to be developed to protect athletes that are participating in these full contact sports. The purpose of this study is to elucidate whether resveratrol decreases brain injury and improves brain function after experiencing a concussion in boxers.

Outcome Measures

Outcome	Result	p-value
PRIMARY Liver Function Testing (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] Ratios) to Screen for Adverse Events.	—	—
SECONDARY Functional Connectivity in Concussed Boxers	—	—
SECONDARY Reaction Time Composite as Assessed by Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) Cognitive Test Performance	—	—

Eligibility Criteria

Inclusion Criteria

Boxers between the ages 18-35 years old
Both men and women
Boxers with an estimated concussion (Mild and Moderate) as estimated by the on-site physician or athletic trainer
Subject has provided full written informed consent prior to the performance of any protocol-specified procedure

Exclusion Criteria

Immediate hospitalization for sports-related concussion (Severe Concussion)
Known inclusion in an interventional clinical trial
Patients with metal implants that would interfere with the MRI scan
Known anemia
Known Pregnancy
Known history of alcohol/drug abuse

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01321151). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.